EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Harnessing Tumor Organoids to Revolutionize Immunotherapy Research

Zhen Wang iD, Peipei Yin, Shizhan Cui, Hui Liu, Dan Li, Yang Yu, Baoshan Cao, Xiaojuan Liu

Cancer Medicine · 2026

DOI: 10.1002/cam4.71776 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2026. Verfasst von Zhen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Organoids, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Peking University Third Hospital, Tianfu Jincheng Laboratory Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has emerged as a revolutionary approach to cancer treatment, yet the lack of robust preclinical testing platforms impedes progress in this field. Tumor organoids, three‐dimensional structures derived from patient‐specific samples, differ from conventional models by faithfully recapitulating the histological, genetic, and phenotypic characteristics of native tumors. Moreover, complex organoid models can partially recapitulate aspects of the tumor microenvironment through the integration of immune cells, vascular‐associated components, and cancer‐associated fibroblasts. This review systematically examines current methodologies for constructing TME‐simulating organoids, along with their applications and future challenges in immunotherapy research, including immune checkpoint inhibitors, cell immunotherapy, bispecific antibodies, oncolytic viruses, and cancer vaccines. By elucidating the advantages and limitations of organoid technology in immunotherapy studies, this review explores its potential to establish a novel platform for predictive evaluation of immunotherapy efficacy. Ultimately, it aims to provide innovative perspectives for future research directions in this field and contribute to enhancing therapeutic outcomes for cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsImmunotherapyNeoplasmsHumansTumor MicroenvironmentAnimalsCancer Vaccines

Stichwörter der Autor:innen

immunotherapyorganoidstumor microenvironment

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China.
  • Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
  • Depatment of Neurology, The 82nd Group Army Hospital of PLA, Baoding, China.
  • College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
  • Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, China.

ORCID-Profile: Zhen Wang

Förderung

  • Peking University Third Hospital
  • Tianfu Jincheng Laboratory Foundation

Zitieren

APA

Wang, Z., Yin, P., Cui, S., Liu, H., Li, D., Yu, Y., Cao, B., & Liu, X. (2026). Harnessing Tumor Organoids to Revolutionize Immunotherapy Research. Cancer Medicine. https://doi.org/10.1002/cam4.71776

Vancouver

Wang Z, Yin P, Cui S, Liu H, Li D, Yu Y, et al. Harnessing Tumor Organoids to Revolutionize Immunotherapy Research. Cancer Medicine. 2026. doi:10.1002/cam4.71776

BibTeX
@article{Wang2026,
  author = {Wang, Zhen and Yin, Peipei and Cui, Shizhan and Liu, Hui and Li, Dan and Yu, Yang and Cao, Baoshan and Liu, Xiaojuan},
  title = {Harnessing Tumor Organoids to Revolutionize Immunotherapy Research},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71776}
}
Kostenlos starten →